Gilead Sciences has entered a partnership Cartography Biosciences to develop treatments for triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) adenocarcinoma. According to the agreement, Cartography will receive an upfront payment of USD 20 million, with additional development, regulatory, and commercial milestones payments, as well as tiered royalties on sales.

During the multi-year collaboration, Gilead will use Cartography’s proprietary technology to discover novel target antigens and pairs of antigens. Cartography’s ATLAS and SUMMIT platforms use target identification algorithms to identify targets, allowing Gilead to employ multiple identified targets to proceed with further research, development, and commercialization of programs against those targets.

Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in areas of HIV, liver diseases, oncology, and inflammatory diseases. The company's product portfolio includes medications such as Biktarvy and Descovy HIV medications for adults and children, and Veklury Covid-19 treatment.